We provide clients with modern medicines and medical products
Innovative preparations of Russian and foreign manufacturers
We work to make more healthy people!
Comfort of delivery, presence in the regions
Social responsibility to consumers
Guaranteed availability of the highest quality products
LLC "Trade house BF" - distribution company operating in the budget and commercial segments of the pharmaceutical market.
The company began supplying medicines in 2013 and is rapidly developing in the Russian pharmaceutical market. Today the company - one of the largest suppliers, strongly occupying the place in supply of medical institutions in all territory of Russia.
The main direction of our activity – is to provide customers with modern medicines and related medical products.
The company's portfolio includes more than 5000 drugs. It contains original and innovative products of Russian and foreign manufacturers, as well as generics of different price categories.
"Trade house BF» offers a wide range of pharmaceutical products at attractive prices.
We try to make our offer competitive on all main indicators – quality and existence of production, level of service, including comfort of Commission of deliveries.
A full cycle of logistics in compliance with the conditions of storage and transportation of drugs in accordance with the requirements of GDP allows you to quickly and correctly deliver to all corners of the country.
A professional team of regional employees in all Federal districts of the Russian Federation is able to quickly offer solutions to the needs of our customers, supplying products for the treatment of any patient.
Our capabilities and services:
A wide range of finished medicines
Flexible terms and methods of placing an order for products
Optimal price-quality ratio for each consumer
Personal Manager for each client
Individual search for drugs for the need
An application for the inclusion of drugs in the list of VED can be submitted through the Internet portal.
January 22, 2019
The Ministry of health announced the changes in the shape and frequency of an applicant's proposals for the inclusion or exclusion of the medicines in the EDL.